Human VEGF₁₆₅ Antibody

Catalog #: AB-293-NA
24 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AB-293-NA

3 Images

All VEGF Antibodies

Product Details

Citations (24)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human VEGF₁₆₅ Antibody Summary

Species Reactivity

Human

Specificity

Detects human VEGF₁₆₅ and human VEGF₁₂₁ in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse VEGF and recombinant rat VEGF is observed.

Source

Polyclonal Goat IgG

Purification

Protein A or G purified

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGF₁₆₅
Ala27-Arg191
Accession # AAV38412

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human VEGF₁₆₅ (Catalog # 293-VE)

Immunohistochemistry

5-15 µg/mL

See below

Neutralization

Measured by its ability to neutralize VEGF₁₆₅-induced proliferation in HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci USA 87:1323. The Neutralization Dose (ND₅₀) is typically 0.600-7.20 µg/mL in the presence of 10 ng/mL Recombinant Human VEGF₁₆₅.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunohistochemistry

VEGF<sub>165</sub>in Human Breast Cancer Tissue.

View Larger

VEGF₁₆₅in Human Breast Cancer Tissue. VEGF₁₆₅was detected in immersion fixed frozen sections of human breast cancer tissue using 5 µg/mL Human VEGF₁₆₅Polyclonal Antibody (Catalog # AB‑293‑NA) overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Neutralization

View Larger

Cell Proliferation Induced by VEGF₁₆₅and Neutralization by Human VEGF Antibody. Recombinant Human VEGF₁₆₅(Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF₁₆₅(10 ng/mL) is neutralized (green line) by increasing concentrations of Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA). The ND₅₀ is typically 0.600-7.20 µg/mL.

Immunohistochemistry

View Larger

VEGF in Human Breast Cancer Tissue. VEGF was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 1 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF

Vascular Endothelial Growth Factor (VEGF or VEGF-A), also known as Vascular Permeability Factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. Human VEGF165 is an approximately 44 kDa molecular weight homodimer sharing 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells. Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity. VEGF165 binds the Semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2. VEGF is required during embryogenesis and functions to regulate the proliferation, migration, and survival of endothelial cells. In adults, VEGF functions mainly in wound healing and the female reproductive cycle. Pathologically, it is involved in tumor angiogenesis and vascular leakage. Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, Oncostatin M (OSM) and TNF-alpha.

Long Name

Vascular Endothelial Growth Factor

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)

Alternate Names

MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human VEGF₁₆₅ Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

24 Citations: Showing 1 - 10
Filter your results:

Filter by:

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients
Authors: Manuel D. Gahete, David Rincón-Fernández, Mario Durán-Prado, Marta Hergueta-Redondo, Alejandro Ibáñez-Costa, Alejandro Rojo-Sebastián et al.
Oncotarget
Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation
Authors: Julia Litvinov, Anna E. V. Hagström, Yubitza Lopez, Meenu Adhikari, Katerina Kourentzi, Ulrich Strych et al.
Biotechnology Letters
Conjugation of Polymer-Coated Gold Nanoparticles with Antibodies—Synthesis and Characterization
Authors: Gamze Tan, Karsten Kantner, Qian Zhang, Mahmoud G. Soliman, Pablo del Pino, Wolfgang J. Parak et al.
Nanomaterials (Basel)
Epithelial–mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy
Authors: Leonardo Rojas‐Puentes, Andrés F. Cardona, Hernán Carranza, Carlos Vargas, Luis F. Jaramillo, Delma Zea et al.
Cancer Medicine
Bioceramic-mediated trophic factor secretion by mesenchymal stem cells enhances in vitro endothelial cell persistence and in vivo angiogenesis
Authors: Jiawei He, Martin L. Decaris, J. Kent Leach
Tissue Engineering Part A
Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers
Authors: Pamela J. Maxwell, Melanie McKechnie, Christopher W. Armstrong, Judith M. Manley, Chee Wee Ong, Jenny Worthington et al.
Molecular Cancer Research
Retinopathy of prematurity shows alterations in Vegfa164 isoform expression
Authors: Olachi J. Mezu-Ndubuisi, Yong-Seok Song, Erica Macke, Hailey Johnson, Ginika Nwaba, Akihiro Ikeda et al.
Pediatric Research
Differentiation-Dependent Secretion of Proangiogenic Factors by Mesenchymal Stem Cells
Authors: Allison I. Hoch, Bernard Y. Binder, Damian C. Genetos, J. Kent Leach
PLoS ONE
Lysophosphatidic Acid Protects Human Mesenchymal Stromal Cells from Differentiation-Dependent Vulnerability to Apoptosis
Authors: Bernard Y.K. Binder, Damian C. Genetos, J. Kent Leach
Tissue Engineering Part A
VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals
Authors: M Yamakuchi, M Okawa, K Takenouchi, A Bibek, S Yamada, K Inoue, K Higurashi, A Tabaru, K Tanoue, Y Oyama, S Higashi, C Fujisaki, H Kanda, H Terasaki, T Sakamoto, Y Soga, T Hashiguchi
PLoS ONE, 2023-04-07;18(4):e0284131.
Species: Human
Sample Types: Serum
Applications: ELISA Development

VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals
Authors: M Yamakuchi, M Okawa, K Takenouchi, A Bibek, S Yamada, K Inoue, K Higurashi, A Tabaru, K Tanoue, Y Oyama, S Higashi, C Fujisaki, H Kanda, H Terasaki, T Sakamoto, Y Soga, T Hashiguchi
PLoS ONE, 2023;18(4):e0284131.
Species: Human
Sample Types: Serum
Applications: ELISA Development

High methylation of lysine acetyltransferase 6B is associated with the Cobb angle in patients with congenital scoliosis
Authors: Y Wu, H Zhang, M Tang, C Guo, A Deng, J Li, Y Wang, L Xiao, G Yang
J Transl Med, 2020-05-24;18(1):210.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

Vasculogenic mimicry formation in EBV-associated epithelial malignancies
Authors: T Xiang, YX Lin, W Ma, HJ Zhang, KM Chen, GP He, X Zhang, M Xu, QS Feng, MY Chen, MS Zeng, YX Zeng, L Feng
Nat Commun, 2018-11-27;9(1):5009.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy
Authors: AM Kivelä, J Huusko, E Gurzeler, A Laine, MH Dijkstra, G Dragneva, CB Andersen, SK Moestrup, S Ylä-Herttu
Sci Rep, 2017-03-24;7(1):386.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
Authors: Lewin J, Khamly K, Young R, Mitchell C, Hicks R, Toner G, Ngan S, Chander S, Powell G, Herschtal A, Te Marvelde L, Desai J, Choong P, Stacker S, Achen M, Ferris N, Fox S, Slavin J, Thomas D
Br J Cancer, 2014-10-16;111(12):2254-61.
Species: Human
Sample Types: Whole Tissue
Applications: IHC

Consumption of a Western-style diet during pregnancy impairs offspring islet vascularization in a Japanese macaque model.
Authors: Pound L, Comstock S, Grove K
Am J Physiol Endocrinol Metab, 2014-05-20;307(1):E115-23.
Species: Primate - Macaca mulatta (Rhesus Macaque)
Sample Types: Whole Tissue
Applications: IHC-P

Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.
Authors: Kondo S, Mukudai Y, Soga D, Nishida T, Takigawa M, Shirota T
Anticancer Res, 2014-02-01;34(2):671-7.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

Extensive podocyte loss triggers a rapid parietal epithelial cell response.
Authors: Hakroush S, Cebulla A, Schaldecker T, Behr D, Mundel P, Weins A
J Am Soc Nephrol, 2013-12-12;25(5):927-38.
Species: Human
Sample Types: Whole Tissue
Applications: IHC

Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.
Authors: Uniewicz KA, Cross MJ, Fernig DG
J. Biol. Chem., 2010-10-18;286(1):12-23.
Species: Human
Sample Types: Buffer
Applications: Complex Application

Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus.
Authors: Nicoletti JN, Shah SK, McCloskey DP, Goodman JH, Elkady A, Atassi H, Hylton D, Rudge JS, Scharfman HE, Croll SD
Neuroscience, 2007-10-26;151(1):232-41.
Species: Rat
Sample Types: Cell Culture Supernates, Whole Tissue
Applications: ELISA Development, IHC

Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.
Authors: Carlile J, 2019, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM
653-664, 2001-09-01;30(8):449-57.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P

The Dose of Growth Factors Influences the Synergistic Effect of Vascular Endothelial Growth Factor on Bone Morphogenetic Protein 4–Induced Ectopic Bone Formation
Authors: Guangheng Li, Karin Corsi-Payne, Bo Zheng, Arvydas Usas, Hairong Peng, Johnny Huard
Tissue Engineering Part A

Platelet-rich plasma decreases fibroblastic activity and woven bone formation with no significant immunohistochemical effect on long-bone healing: An experimental animal study with radiological outcomes
Authors: İbrahim Deniz Canbeyli, Rahmi Can Akgun, Orcun Sahin, Aysen Terzi, İsmail Cengiz Tuncay
J Orthop Surg (Hong Kong)

Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones
Authors: William W. Yuen, Nan R. Du, Chun H. Chan, Eduardo A. Silva, David J. Mooney
Proceedings of the National Academy of Sciences